Influence of ABCB1 gene polymorphism on rivaroxaban pharmacokinetics

Abstract

This article presents the comparison of the pharmacogenetic and pharmacokinetic testing results in patients with atrial fibrillation taking rivaroxaban. The role of ABCB1 gene polymorphism in the variability of the pharmacological response was assessed, and the possibility of personalized treatment using therapeutic drug monitoring was discussed.

Keywords

pharmacogenetics / therapeutic drug monitoring / genetic biomarkers / rivaroxaban / single-nucleotide polymorphisms / P-glycoprotein / ABCB1

References

[1] Patel MR for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation. 2010;122 (Suppl 21):2217.

[2] Patel M.R. for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) // Circulation. 2010. Vol. 122. N Suppl 21. P. 2217.

[3] Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262–270. doi: 10.1038/sj.tpj.6500313.

[4] Wadelius M., Chen L.Y., Downes K., Ghori J., Hunt S., Eriksson N., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose // Pharmacogenomics J. 2005. Vol. 5. N 4. P. 262–270. doi: 10.1038/sj.tpj.6500313.

[5] Zimetbaum P. In the clinic atrial fibrillation. Ann Intern Med. 2010;153(11):ITC6. doi: 10.7326/0003-4819-153-11-201012070-01006.

[6] Zimetbaum P. In the clinic atrial fibrillation // Ann Intern Med. 2010. Vol. 153. N 11. P. ITC6. doi: 10.7326/0003-4819-153-11-201012070-01006.

[7] Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrialfibrillation using a novelrisk factor-based approach: the EuroHeart Survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi: 10.1378/chest.09-1584.

[8] Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrialfibrillation using a novelrisk factor-based approach: the EuroHeart Survey on atrial fibrillation // Chest. 2010. Vol. 137. N 2. P. 263–272. doi: 10.1378/chest.09-1584.

[9] ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J. 2010;31:2369–2429.

[10] ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation // Eur Heart J. 2010. Vol. 31. P. 2369–2429.

[11] Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429. doi: 10.1093/eurheartj/ehq278.

[12] Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // Eur Heart J. 2010. Vol. 31. N 19. P. 2369–2429. doi: 10.1093/eurheartj/ehq278.

[13] Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–1413. doi: 10.1093/europace/eus305.

[14] Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Europace. 2012. Vol. 14. N 10. P. 1385–1413. doi: 10.1093/europace/eus305.

[15] Rekomendatsii RKO, VNOA i ASSKh. Diagnosis and treatment of atrial fibrillation. Moscow; 2012. (In Russ).

[16] Рекомендации РКО, ВНОА и АССХ. Диагностика и лечение фибрилляции предсердий. M. , 2012.

[17] January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267. doi: 10.1161/CIR.0000000000000041.4.

[18] January C.T., Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C. Jr, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society // Circulation. 2014. Vol. 130. N 23. P. e199–267. doi: 10.1161/CIR.0000000000000041.4.

[19] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638.

[20] Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation // N Engl J Med. 2011. Vol. 365. N 10. P. 883–891. doi: 10.1056/NEJMoa1009638.

[21] Beyer-Westendorf J, Foerster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–962. doi: 10.1182/blood-2014-03-563577.

[22] Beyer-Westendorf J., Foerster K., Pannach S., Ebertz F., Gelbricht V., Thieme C., et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry // Blood. 2014. Vol. 124. N 6. P. 955–962. doi: 10.1182/blood-2014-03-563577.

[23] Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017;43(3):277–290. doi: 10.1055/s-0036-1597296.

[24] Douxfils J., Gosselin R.C. Laboratory assessment of direct oral anticoagulants // Semin Thromb Hemost. 2017. Vol. 43. N 3. P. 277–290. doi: 10.1055/s-0036-1597296.

[25] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 200;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.

[26] Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F. 3rd, Feldman H.I., et al. A new equation to estimate glomerular filtration rate // Ann Intern Med. 2009. Vol. 150. N 9. P. 604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.

[27] Rodina TA, Mel’nikov ES, Aksenov AA, Belkov SA, Sokolov AV, Prokof’ev AB, Ramenskaya GV. Development of an HPLC-MS/MS method for quantitative determination of rivaroxaban in human blood serum. Pharmaceutical Chemistry Journal. 2018;52(4):372–377.

[28] Rodina T.A., Mel’nikov E.S., Aksenov A.A., Belkov S.A., Sokolov A.V., Prokof’ev A.B., Ramenskaya G.V. Development of an HPLC-MS/MS method for quantitative determination of rivaroxaban in human blood serum // Pharmaceutical Chemistry Journal. 2018. Vol. 52. N 4. P. 372–377.

RIGHTS & PERMISSIONS

Eco-Vector